{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_name in Any Name (approximate match)
Status:
Investigational
Source:
NCT03631706: Phase 3 Interventional Completed Non-small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02544438: Phase 1/Phase 2 Interventional Completed Acute Myeloid Leukemia
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03846453: Phase 3 Interventional Completed Dry Eye
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03858634: Phase 2 Interventional Completed Chronic Idiopathic Urticaria
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04692181: Phase 1/Phase 2 Interventional Active, not recruiting Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04295538: Phase 2 Interventional Active, not recruiting Spinal Cord Injury (SCI)
(2020)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
INN:mirvetuximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00035880: Phase 2/Phase 3 Interventional Completed Graft Vs Host Disease
(1999)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Depelestat is a small-protein neutrophil elastase (NE) inhibitor. The elastase at the neutrophil surface was fully inhibited by depelestat and formed soluble complexes. The elastase in cystic fibrosis sputum supernatants was inhibited by stoichiometric amounts of depelestat, allowing titration of the protease. But the percentage of inhibition in whole sputum homogenates varied from 50 to 100%. Depelestat could reduce neutrophil trans-epithelial migration and reduce activity released from neutrophils and NE-induced cytokine expression in airway epithelial cells. NE inhibition could be useful in managing neutrophilic airway inflammation in cystic fibrosis.
